FGF19 and metabolic dysfunction-associated steatohepatitis: Among these compounds, cilofexor and TERN-101 (NCT04328077) display positive effects in patients with NASH in phase I and II clinical trials.382,383 In a phase I study, although cilofexor has no effect on cholesterol, it dose-dependently reduces the level of FGF19 (NCT02654002).